Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Repurposing antihistamines to reduce treatment-related toxicity for children with WNT-medulloblastoma
Investigating the preclinical efficacy of albendazole in paediatric acute myeloid leukaemia
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma
Enhancing CAR T-cell expansion and prolonged persistence for the effective treatment of paediatric medulloblastoma
ALLTogether1 CSF-FLOW Study
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia